Oxford Asset Management’s Zosano Pharma Corporation ZSAN Stock Holding History

Oxford Asset Management’s Portfolio ZSAN Stock Details ZSAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,075	Closed	-$57K	–	1555
2019 Q4	$57K	Buy	+1,075	New	+$66.3K	﹤0.01%	1661
2019 Q1	–	Sell	-370	Closed	-$27K	–	2111
2018 Q4	$27K	Buy	+370	New	+$46.8K	﹤0.01%	1730

Other funds holding ZSAN

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BBVA

Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Oxford Asset Management's ZSAN Position: Q1 2020 in Review

Oxford Asset Management sold out of Zosano Pharma Corporation (ZSAN) in Q1 2020, closing a stake of 1,075 shares — an estimated $57K sold.

Oxford Asset Management first reported a position in ZSAN in Q4 2018 and held it in 2 quarters. The position peaked at $57K in Q4 2019. 29 funds tracked by Wall St. Rank hold ZSAN as of Q1 2020.

Oxford Asset Management reported no remaining Zosano Pharma Corporation position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 1,075 Zosano Pharma Corporation shares in Q1 2020, an estimated $57K.
Oxford Asset Management first reported a position in Zosano Pharma Corporation in Q4 2018 and held it in 2 quarters.
Oxford Asset Management's Zosano Pharma Corporation position peaked at $57K in Q4 2019.
29 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.